Welcome to our dedicated page for Teladoc Health SEC filings (Ticker: TDOC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Teladoc Health filings document the company’s virtual care operations, financial reporting, governance structure, equity compensation practices, and common-stock matters. Recent Form 8-K reports furnish quarterly and annual results releases, including segment disclosures for Integrated Care and BetterHelp, adjusted EBITDA measures, outlook commentary, and cash-flow information.
The company’s proxy and current reports also disclose board composition, director appointments and retirements, audit, compensation, and nominating and corporate governance committee assignments, director independence determinations, and non-employee director compensation arrangements. Other filings cover amendments to the 2023 Employment Inducement Incentive Award Plan, shares reserved for issuance, inducement awards, Regulation FD exhibits, and related governance disclosures under NYSE and SEC rules.
Anquillare Mark V reported acquisition or exercise transactions in this Form 4 filing.
Teladoc Health, Inc. reported that director Mark V. Anquillare received a grant of 37,425 Restricted Stock Units on 2026-08-03, each representing a contingent right to one share of common stock. One-third of the units vest on the first anniversary of the grant, with the remainder vesting in eight substantially equal quarterly installments, leaving him with 37,425 RSUs directly held after the award.
Teladoc Health, Inc. identifies Mark V Anquillare as a reporting person by submitting an initial statement of beneficial ownership on Form 3 in his capacity as a director. The statement lists no equity transactions and includes a remark referencing Exhibit 24 — Power of Attorney.
Teladoc Health, Inc. increased its Board of Directors to ten members and appointed Mark V. Anquillare as an independent director effective August 3, 2026. He joins both the audit and compensation committees and has been designated an “audit committee financial expert” under SEC and New York Stock Exchange rules.
The company states there are no related-party arrangements or transactions requiring disclosure in connection with his appointment. Anquillare will receive the same indemnification protections and be eligible for the standard compensation programs for Teladoc Health’s non‑employee directors. A press release announcing his appointment was issued on August 3, 2026.
Teladoc Health, Inc. reported lower revenue and continued losses for the quarter ended June 30, 2026. Revenue was $606,927 (thousands), down from $631,900 (thousands) a year earlier, as growth in the Integrated Care segment only partly offset declines in BetterHelp revenue and paying users.
Net loss for the quarter increased to $38,908 (thousands), while loss from operations narrowed versus the prior year due to reduced advertising, marketing, and overhead spending. Adjusted EBITDA was $65,713 (thousands), slightly below 2025 levels. BetterHelp Paying Users fell 11% to 0.346 million, and management highlighted ongoing pressure from a shift toward insurance-covered services. In Integrated Care, U.S. members declined about 2% to 100.3 million, but chronic care program enrollment rose 14% to 1.272 million. Cash and cash equivalents were $774,348 (thousands), and the company carries $1,000,000 (thousands) of 1.25% convertible senior notes due 2027, now classified as current. A goodwill impairment test for the BetterHelp reporting unit identified no impairment, though management notes that future performance or share-price changes could trigger additional testing.
Teladoc Health reported Second Quarter 2026 revenue of $606.9 million, down 4% year over year, and a net loss of $38.9 million, or $0.21 per share. Adjusted EBITDA was $65.7 million, a 5% decrease from the prior year, and results were within previously communicated consolidated guidance ranges.
The Integrated Care segment generated revenue of $394.3 million, up 1%, with adjusted EBITDA of $65.2 million and a 16.5% margin, compared with 14.7% a year earlier. U.S. Integrated Care members totaled 100.3 million and chronic care program enrollment rose 14% to 1.272 million. BetterHelp revenue declined 12% to $212.6 million, and adjusted EBITDA fell to $0.5 million, a 0.2% margin, amid weaker cash-pay demand and rapid growth in insurance-covered services.
For the first six months of 2026, revenue declined 3% to $1.22 billion and net loss was $102.7 million, versus $125.7 million in 2025, when results included a $59.1 million non-cash goodwill impairment. Second Quarter 2026 operating cash flow was $64.7 million and free cash flow $35.7 million. For full-year 2026, Teladoc forecasts revenue of $2.362–$2.447 billion, adjusted EBITDA of $271–$303 million, free cash flow of $130–$170 million, and a net loss per share between $1.00 and $0.75.
Teladoc Health, Inc. executive Kelly Bliss, President of U.S. Group Health, sold 2,500 shares of Teladoc common stock in an open-market transaction at $9.50 per share. The sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on August 14, 2025. After this sale, she directly holds 84,878 Teladoc shares.
Teladoc Health, Inc. Chief Accounting Officer Joseph Ronald Catapano reported the vesting of restricted stock units and a related share sale. On July 1, 2026, 2,083 restricted stock units converted into the same number of common shares at a conversion price of $0.00 per share. According to the footnotes, these units convert to Teladoc common stock on a one-for-one basis and relate to a 25,000-unit grant awarded on October 1, 2024.
On July 2, 2026, 653 common shares were sold at $9.10 per share. A footnote explains that these shares were sold to cover the tax withholding obligation arising from the RSU vesting, indicating a compensation-related, non-discretionary sale rather than an ordinary portfolio transaction. Following these transactions, Catapano directly holds 12,267 Teladoc common shares, and 10,418 restricted stock units remain outstanding.
TDOC filing a Form 144 notice for proposed resale of 2,500 shares of Common Stock pursuant to restricted stock vesting on 03/19/2025. The filing also discloses recent open-market sales by Kelly M. Bliss of 7,679, 2,500, and 2,500 shares on 06/02/2026, 06/29/2026, and 07/01/2026, with dollar amounts reported alongside each sale.
Teladoc Health, Inc. executive Kelly Bliss, President, U.S. Group Health, sold 2,500 shares of common stock in an open-market transaction at $9.00 per share, totaling $22,500. After the sale, she directly holds 87,378 shares. The transaction was executed under a Rule 10b5-1 trading plan adopted on August 14, 2025.
TDOC filed Form 144 reporting sales and recent restricted‑stock vesting for Common stock. The filing lists restricted stock vesting of 118 shares on 03/19/2025 and 2,382 shares on 06/01/2025. It also reports sales of 7,679 shares for $58,567.73 on 06/02/2026 and 2,500 shares for $21,250.00 on 06/29/2026.